MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 09/19/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. ROIV, QGEN, BBIO, MRNA, ELAN, VRNA, RVMD, GRFS, RYTM, and LEGNShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Roivant Sciences (ROIV), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Roivant Sciences QIAGEN BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Roivant Sciences (NASDAQ:ROIV) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Which has preferable valuation and earnings, ROIV or MOR? Roivant Sciences has higher earnings, but lower revenue than MorphoSys. Roivant Sciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$23.23M433.25-$171.98M-$0.70-21.06MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more risk and volatility, ROIV or MOR? Roivant Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Is ROIV or MOR more profitable? MorphoSys has a net margin of -226.79% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-2,111.79% -15.90% -14.95% MorphoSys -226.79%-694.31%-22.55% Do analysts recommend ROIV or MOR? Roivant Sciences currently has a consensus target price of $19.94, suggesting a potential upside of 35.26%. Given Roivant Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Roivant Sciences is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ROIV or MOR? In the previous week, Roivant Sciences had 50 more articles in the media than MorphoSys. MarketBeat recorded 50 mentions for Roivant Sciences and 0 mentions for MorphoSys. Roivant Sciences' average media sentiment score of 0.94 beat MorphoSys' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Overall Sentiment Roivant Sciences Positive MorphoSys Neutral Do institutionals and insiders have more ownership in ROIV or MOR? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryRoivant Sciences beats MorphoSys on 13 of the 17 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$873.86M$5.77B$10.51BDividend YieldN/A4.84%5.53%4.57%P/E Ratio-5.451.1976.4326.62Price / Sales11.99114.73519.46112.55Price / CashN/A17.6437.4661.85Price / Book54.176.4613.616.45Net Income-$205.35M-$5.56M$3.29B$271.57M7 Day PerformanceN/A0.53%1.87%2.61%1 Month PerformanceN/A5.75%4.03%7.28%1 Year PerformanceN/A25.85%77.41%29.60% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ROIVRoivant Sciences3.4223 of 5 stars$14.94-0.7%$19.94+33.5%+23.9%$10.27B$29.05M-21.34860Trending NewsInsider TradeAnalyst RevisionQGENQIAGEN4.3622 of 5 stars$45.72-0.5%$49.69+8.7%+5.5%$10.21B$1.98B27.015,765BBIOBridgeBio Pharma4.4951 of 5 stars$51.54-1.6%$63.94+24.1%+102.8%$10.01B$221.90M-12.60400MRNAModerna4.4574 of 5 stars$26.56+5.2%$41.81+57.4%-59.8%$9.82B$3.24B-3.535,800Trending NewsELANElanco Animal Health2.5844 of 5 stars$19.08-0.6%$17.33-9.2%+28.5%$9.54B$4.44B22.199,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.0305 of 5 stars$106.25+0.2%$109.00+2.6%+259.0%$9.14B$42.28M-107.3230Positive NewsRVMDRevolution Medicines4.2884 of 5 stars$44.41+2.0%$73.67+65.9%+3.7%$8.14B$11.58M-9.87250GRFSGrifols3.9122 of 5 stars$9.70-0.4%$10.30+6.2%+11.9%$6.70B$7.81B8.2923,822Positive NewsRYTMRhythm Pharmaceuticals3.2028 of 5 stars$99.00+3.1%$101.57+2.6%+93.3%$6.38B$130.13M-32.89140Positive NewsLEGNLegend Biotech3.148 of 5 stars$34.08+0.2%$74.22+117.8%-28.3%$6.28B$627.24M-38.732,609Positive News Related Companies and Tools Related Companies ROIV Competitors QGEN Competitors BBIO Competitors MRNA Competitors ELAN Competitors VRNA Competitors RVMD Competitors GRFS Competitors RYTM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOR Stock Alerts